– USA, CA – Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced the appointment of Dr. Dirk Sauer (Ph.D.) to its Board of Directors, effective April 13, 2022, succeeding Dr. Gerald Cagle who is retiring from the Board.
Dr. Sauer will also join the Nomination and Corporate Governance Committee. He will also chair the Science and Innovation Committee.
About Dr. Dirk Sauer
Dr. Dirk Sauer is an expert in global pharmaceutical development with more than 30 years of experience in ophthalmology and neuroscience. He successfully led numerous projects and teams during all phases of the drug development process. Before retiring from Novartis in 2021, Dr. Sauer led the company’s Ophthalmology Development Unit for more than nine years, and during that time built a development portfolio for treatments of both the back and front of the eye, including small molecules, biologics, gene therapies, and digital therapeutics.
Dr. Sauer joined Ciba-Geigy in 1989 as a postdoctoral fellow in the Neuroscience Preclinical Research Department. He subsequently held various positions of increasing responsibilities within preclinical, clinical research, and project management working on acute and chronic neurodegenerative diseases such as stroke, head trauma, Parkinson’s disease, Alzheimer’s disease, and ALS at Ciba-Geigy and Novartis. In 2005, Dr. Sauer joined the Ophthalmology Business Unit at Novartis as Senior Global Project Leader for Visudyne and Lucentis. In 2011, Dr. Sauer was appointed Global Development Unit Head for the Novartis Ophthalmology Development Unit, which subsequently included the development unit of the former Alcon Pharma franchise.
Dr. Sauer has a degree in Pharmacy from the University of Münster, and a Ph.D. in Pharmacology from the University of Marburg, Germany.
About Graybug
Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases. The company’s diversified portfolio is designed to treat vision-threatening diseases of the retina, optic nerve, and cornea, by either maintaining effective drug levels in ocular tissues for long periods, or using innovative technologies, such as injectable sustained-release formulations, or curing diseases with gene therapies. Graybug’s most advanced drug candidate, GB-102 is a microparticle formulation of a pan-VEGF inhibitor, sunitinib, for the treatment of wet age-related macular degeneration designed for a twice-per-year intravitreal injection. GB-102 has the potential to also benefit patients with diabetic retinopathy. GB-401 is a first-in-class implant formulation containing a novel prodrug of timolol for the treatment of primary open-angle glaucoma designed for a twice-per-year intravitreal injection with a proprietary applicator. GB-501 is an adeno-associated virus gene therapy with Orphan Drug Designation and Rare Pediatric Disease Designation to treat corneal clouding caused by mucopolysaccharidosis type 1, a lysosomal storage disorder. GB-601 is being developed as a long-acting formulation of a novel cGMP analog to address hereditary retinal diseases like retinitis pigmentosa, a group of genetic disorders that involve a loss of cells in the retina. GB-701 is being developed as a long-acting formulation of a potent factor B inhibitor targeting the complement cascade which plays a role in AMD. Founded in 2011 based on technology licensed from the Johns Hopkins University School of Medicine, Graybug has offices in Redwood City, California, and Baltimore, Maryland.
For more information: https://www.graybug.vision/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
